Orphan Drugs To Make Up 16% Of Rx Market By 2018, Says Evaluate Pharma
This article was originally published in The Pink Sheet Daily
Executive Summary
The health care consultancy released a report that shows the rapid growth of the orphan drug sector as companies take advantage of incentives. Orphan oncologic drugs dominate the market, and Novartis is slated to lead in orphan sales by 2018.